Shenzhen Hepalink Pharmaceutical Group Co (HKSE:09989) Ending Cash Position : HK$2,371 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position?

Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Jun. 2024 was HK$2,371 Mil.

Shenzhen Hepalink Pharmaceutical Group Co's quarterly Ending Cash Position increased from Dec. 2023 (HK$1,931 Mil) to Mar. 2024 (HK$2,290 Mil) and increased from Mar. 2024 (HK$2,290 Mil) to Jun. 2024 (HK$2,371 Mil).

Shenzhen Hepalink Pharmaceutical Group Co's annual Ending Cash Position declined from Dec. 2021 (HK$1,812 Mil) to Dec. 2022 (HK$1,474 Mil) but then increased from Dec. 2022 (HK$1,474 Mil) to Dec. 2023 (HK$1,931 Mil).

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Historical Data

The historical data trend for Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Chart

Shenzhen Hepalink Pharmaceutical Group Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Ending Cash Position

Get a 7-Day Free Trial

1,197.92

1,576.92

1,811.76

1,473.74

1,931.23

Shenzhen Hepalink Pharmaceutical Group Co Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Ending Cash Position	Get a 7-Day Free Trial															1,572.92	1,885.58	1,931.23	2,290.34	2,371.32

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	1443.468	+	487.757
	=	1,931

Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position for the quarter that ended in Jun. 2024 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2269.768	+	101.554
	=	2,371

Shenzhen Hepalink Pharmaceutical Group Co Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Shenzhen Hepalink Pharmaceutical Group Co's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Shenzhen Hepalink Pharmaceutical Group Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shenzhen Hepalink Pharmaceutical Group Co Ltd (HKSE:09989) » Definitions » Ending Cash Position

Traded in Other Exchanges

002399:China

Address

No. 21 Langshan Road, Songping Mountain, Guangdong Province, Nanshan District, Shenzhen, CHN, 518057

Website

https://www.hepalink.com

Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company engaged in biopharmaceutical production, biopharmaceutical services, biopharmaceutical trading, and biopharmaceutical research and development. The company distributes its products both in the domestic and overseas markets. The Group mainly operates three main business segments, including the Finished dose pharmaceutical products business; Active pharmaceutical ingredients; CDMO business, and Others. The geographical presence of the company is in Hong Kong, the United States of America, Europe, Mainland China, and Other countries. The majority of the company's revenue comes from USA and Europe.

Executives

Hong Ze Jun	2101 Beneficial owner
Orbimed Capital Llc	2102 Investment manager
Morgan Stanley & Co. International Plc	2105 Underwriter
Morgan Stanley International Holdings Inc.	2201 Interest of corporation controlled by you
Morgan Stanley International Limited	2201 Interest of corporation controlled by you
Morgan Stanley Investments (uk)	2201 Interest of corporation controlled by you
Avict Global Holdings Limited	2101 Beneficial owner
Worldwide Healthcare Trust Plc	2101 Beneficial owner

Shenzhen Hepalink Pharmaceutical Group Co Headlines

No Headlines